Litcius/Paper detail

A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG Oncology/GOG study

Victoria Bae‐Jump, Michael W. Sill, Paola A. Gehrig, K. Moxley, Andrea R. Hagemann, Steven Waggoner, Roisin E. O’Cearbhaill, M. McDonald, Paul DiSilvestro, Paul W. Sperduto, Carol Aghajanian

2020Gynecologic Oncology20 citationsDOIOpen Access PDF

Topics & Concepts

CarboplatinMedicinePaclitaxelEndometrial cancerOncologyTolerabilityInternal medicineMetforminPlaceboStage (stratigraphy)ChemotherapyCancerGynecologyCisplatinAdverse effectBiologyInsulinAlternative medicinePaleontologyPathologyMetabolism, Diabetes, and CancerCancer, Lipids, and MetabolismEndometrial and Cervical Cancer Treatments
A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG Oncology/GOG study | Litcius